Post-earnings recap
Reported
Thu, Oct 26, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that BioMarin Pharmaceutical is facing difficulties, particularly reflected in the EPS miss. The stock reacted negatively, dropping 2.67%, likely due to investor concerns about the company's current challenges and lack of guidance. Without clear direction, investors may remain cautious in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | -63.25% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions impacting performance. They are focused on navigating these challenges effectively.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.